Insiders who reported open-market trades in the last 12 months at the companies Nur Nicholson files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Nur Nicholson is a corporate insider, tracked as Chief Technology Officer of Kailera Therapeutics, Inc. (KLRA). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Nur Nicholson submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has Nur Nicholson been buying or selling stock?
Recorded transactions: 0 open-market purchases and 3 open-market sales ($270K) across all tracked filings.
Nur Nicholson is Chief Technology Officer of Kailera Therapeutics, Inc. (KLRA). 6 SEC Form 4 filings on record, most recently on 9 September 2026. Most recent open-market trade: sold $168K of APLS on 23 January 2026. Lifetime open-market sales: $270K.
Recent transactions
17
The latest 17 SEC Form 4 transactions reported by Nur Nicholson.
InsiderAlpha's records for Nur Nicholson go back to 2026: 6 primary Form 4 filings, an average of 6.0 per year. No recorded transaction carries a Rule 10b5-1 plan flag. An absent flag does not establish whether a transaction was pre-arranged or discretionary.
